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We read with a great interest the recently published retrospective propensity-matched analysis 
by Goksedef D et al
1
. The authors matched 58 patients: recombinant activated factor VII 
(rFVII)-treated group (n=29) and non-rFVII-treated group (n=29)
1
. Patients were compared 
on re-exploration, mortality, bleeding-related events, use of blood and blood products, length 
of intensive care unit stay, duration of hospitalization, and thrombotic complications
1
. We 
agree with authors’ statement that strategies to prevent coagulopathic bleeding are essential 
for the successful management of patients undergoing complex aortic operations. However, 
we have few comments and suggestions for haemostatic management in such complex 
patients. 
In our opinion, data regarding preoperative antiplatelet therapy management are lacking. We 
are interested whether matched patients were preoperatively exposed to antiplatelet therapy 
(i.e. aspirin). Was proportion of patients exposed to antiplatelet therapy different among the 
matched groups? There is an evidence that certain patients have an accentuated response to 
the usual doses of preoperative aspirin that may result in increased perioperative blood loss
2
. 
Thus, the use of point-of-care suitable platelet function analyzers seem to be reasonable in 
this field. Such an approach in preoperative phase can detect patients with accentuated platelet 
inhibition and allow possibility for early discontinuation of antiplatelet drugs prior to surgery 
in patients with intensive platelet inhibition. 
Furthermore, the results of study by Goksedef et al
1
 are not in line with recently published 
results by Chapman AJ et al
3
 who also compared cardiosurgical patient outcomes with respect 
to rFVII administration
3
. In study by Chapman AJ et al
3
, group of patients treated with rFVII 
did have significantly higher rate of re-operation for bleeding, a two fold increase in the use 
of blood products, and, more frequently, had pulmonary complications
3
. In addition to, 
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Hacquard et al 
4
 reported 20% of patients with rFVII administration who continued to bleed 
severely despite rFVII therapy.  
In our opinion, rFVII presents valuable therapeutic option in cases of intractable bleeding. 
However, rFVII should be administered after other useful treatment modalities are exhausted. 
For example, Spiess BD et al
5
 reported thromboelastography guided hemostatic management 
to significantly reduce incidence of overall transfusion and mediastinal re-exploration due to 
excessive bleeding
5
. In addition to, the preliminary results of our research project under 
ClinicalTrials.gov Identifier: NCT01281397 (data not published, manuscript under 
preparation) showed modified rotational thromboelastometry and multiple electrode 
aggregometry results as predictors of excessive bleeding after cardiac surgery procedures. 
Preoperative platelet function assessment and intraoperative hemostatic properties 
optimization guided by thromboelastometry can reduce proclivity to excessive bleeding, 
therefore, lead to diminished use of rFVII, with even better rFVII efficiency after functional 
hemostatic properties optimization prior to rFVII administration. Noteworthy, concomitant 
use of multiple electrode aggregometry and modified rotational thromboelastometry can help 
to define excessive bleeding as a surgical or a coagulopathic bleeding. rVII administration 
should follow previously mentioned pre- and intraoperative haemostatic optimization 
measures based on bedside suitable haemostatic monitoring devices with a short time frame 
from blood sampling to getting results. In our experience, such an algorithm can help in 
reducing both chest tube output and blood products transfusion requirements with only 
sporadically need for rFVII administration.  
We congratulate the authors on their elegant and timely research. 
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